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ABSTRACT
Objective Altitude- related and exercise- related 
elevations in blood pressure (BP) increase the likelihood 
of developing pulmonary hypertension and high- altitude 
illness during high- altitude sojourn. This study examined 
the antihypertensive effect and potential exercise benefit of 
the angiotensin II receptor antagonist losartan when taken 
at altitude.
Methods Twenty participants, paired for age and ACE 
genotype status, completed a double- blinded, randomised 
study, where participants took either losartan (100 mg/day) 
or placebo for 21 days prior to arrival at 5035 m (Whymper 
Hut, Mt Chimborazo, Ecuador). Participants completed 
a maximal exercise test on a supine cycle ergometer at 
sea level (4 weeks prior) and within 48 hours of arrival 
to 5035 m (10- day ascent). Power output, beat- to- beat 
BP, oxygen saturation (SpO
2
) and heart rate (HR) were 
recorded during exercise, with resting BP collected from 
daily medicals during ascent. Before and immediately 
following exercise at 5035 m, extravascular lung water 
prevalence was assessed with ultrasound (quantified via 
B- line count).
Results At altitude, peak power was reduced relative 
to sea level (p<0.01) in both groups (losartan vs placebo: 
down 100±29 vs 91±28 W, p=0.55), while SpO
2
 (70±6 
vs 70±5%, p=0.96) and HR (146±21 vs 149±24 bpm, 
p=0.78) were similar between groups at peak power, as 
was the increase in systolic BP from rest to peak power 
(up 80±37 vs 69±33 mm Hg, p=0.56). Exercise increased 
B- line count (p<0.05), but not differently between groups 
(up 5±5 vs 8±10, p=0.44).
Conclusion Losartan had no observable effect on resting 
or exercising BP, exercise- induced symptomology of 
pulmonary hypertension or performance at 5035 m.
INTRODUCTION
Altitude and dynamic exercise both increase 
arterial blood pressure (BP).1 2 This informa-
tion is of increasing relevance to standard 
clinical practice given the increasing numbers 
of individuals with pre- existing cardiovascular 
conditions (eg, hypertension) sojourning at 
high altitude.3 Moreover, BP management 
is essential in the high- altitude setting since 
pulmonary hypertension can precipitate the 
development of high altitude pulmonary 
oedema (HAPE).4 The worrying symptom-
ology of HAPE, including fatigue, dyspnoea 
and the potential for death, has made 
prophylaxis and treatment an important 
aspect of modern altitude medicine.5 The 
antihypertensive actions of nifedipine and 
dexamethasone have been shown to decrease 
arterial BP (although not consistently6), 
pulmonary artery pressure, and reduce the 
incidence of HAPE.6 7
Pharmacological inhibition of the renin- 
angiotensin- aldosterone system (RAAS) 
could also be beneficial for HAPE prevention 
and may also improve exercise performance 
at altitude. Support for how RAAS inhibition 
may prevent HAPE lies within genetic studies, 
which have demonstrated that genetic 
What are the findings?
 ► Losartan, an angiotensin II type- I receptor antago-
nist, had no observable effect on either resting or 
exercise blood pressure responses at 5035 m, nor 
did it reliably reduce exercise- induced symptomol-
ogy of pulmonary hypertension or improve arterial 
saturation.
 ► Losartan did not improve exercise performance at 
5035 m.
How might it impact on clinical practice in the 
future?
 ► Findings of a null effect on blood pressure manage-
ment has implications for hypertensive individuals 
currently receiving antihypertensive treatment who 
travel to high altitudes, as they may be at greater risk 
for high altitude illness and cardiovascular events 
than the normotensive individuals tested herein.
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polymorphisms among RAAS- associated candidate genes 
are related with the physiologic response to hypoxic expo-
sure.8 9 For example, polymorphisms in the ACE gene 
(eg, I/I vs D/D genotype) appear to partly contribute to 
the heterogeneity displayed in the susceptibility to high- 
altitude illness.10 Further, the I allele is more frequently 
found in climbers who successfully reach over 8000 m and 
has been associated with the ability to maintain higher 
arterial oxygenation at altitude, a greater hypoxic venti-
latory drive, higher endurance performance at sea level, 
as well as better high- altitude adaptation.8 10 11 Parati et 
al have previously demonstrated the anti- hypertensive 
effects of RAAS inhibition (via telmisartan, 80 mg dose) 
during exposure to high altitude,12 however, the poten-
tial of RAAS inhibition to improve exercise performance 
at altitude remains unknown, as does its ability to reduce 
exercise- induced evidence of pulmonary hypertension 
(eg, increases in extravascular lung water (EVLW)).13 
Interestingly, Kiely et al reported that losartan, an angio-
tensin II receptor antagonist, reduced both systemic BP 
and pulmonary vascular resistance in response to acute 
graded hypoxic exposure.14 Whether this laboratory- 
based observation translates to the sustained hypoxic 
exposure of the high- altitude setting remains to be deter-
mined.
Therefore, the purpose of this study was to evaluate the 
effects of the angiotensin II receptor antagonist, losartan, 
on BP during ascent and to determine whether it could 
improve exercise performance at 5035 m. We hypoth-
esised that blockade of the angiotensin receptor would 
reduce altitude- related increases in resting and exer-
cising BP, reduce the effect of strenuous exercise on the 
development of EVLW at high altitude, and ultimately 
improve exercise performance via enhanced pulmonary 
ventilation (V
E




Twenty participants (14 male, 6 female) free of any pre- 
existing conditions were included in the study. None of 
the participants had slept at high altitude (ie, >2500 m) 
in the 3 months prior to the experiment. ACE genotyping 
(II, ID or DD) was performed for each participant prior 
to pair- matching participants for ACE genotype, age, sex 
and previous altitude exposure. Following matching, 
a double- blind, randomised, placebo- controlled trial 
design was adopted in which individuals within each pair 
were randomly assigned to either placebo or losartan 
groups. Losartan (100 mg/day or placebo) and placebo 
(starch) administration began in the UK 21 days prior 
to departure for Quito, Ecuador (2850 m). On arrival at 
Quito, participants ascended over 8 days to the Whymper 
Hut on the flank of Chimborazo volcano (5035 m). 
Within 48 hours of arrival to 5035 m, each pair of partici-
pants (within ~1 hour of each other) completed a graded 
maximal aerobic capacity exercise test. Further details 
of participant genotype pairing, losartan administration 
and ascent profile have been previously published as part 
of another study conducted on this expedition.15
Baseline and daily measures
Baseline measures of BP and exercise performance 
were recorded at sea- level and before losartan/placebo 
administration (~4 weeks prior to ascent). During ascent, 
measures of resting systolic and diastolic BPs (SBP and 
DBP) were collected each morning using a manual 
sphygmomanometer as part of the routine medical exam-
ination.
Exercise protocol and measures
Sea-level exercise test
Baseline sea- level maximal exercise tests were conducted 
4 weeks prior to ascent. This test consisted of a graded 
exercise test to volitional fatigue16 on a cycle ergom-
eter (Alticycle) designed for altitude studies.17 Maximal 
power output (Watt
max
) was determined and heart rate 
(HR) recorded via short range telemetry (Polar Electro, 
UK). These data were used to calculate the intensity steps 
for high- altitude exercise tests and to determine maximal 
power output for this exercise modality (supine cycling).
Altitude exercise test
Participants were instrumented and then rested for at 
least 2 min while pre- exercise measurements of oxygen 
uptake (VO
2
), carbon dioxide production, V
E
, HR, SBP, 
and DBP were collected. Participants undertook a 5 min 
self- paced warm- up and a modified graded exercise 
test on the Alticycle. This modified graded exercise test 
began at an intensity of 30% of sea- level Watt
max
, with 
10% increases every 3 min up to 80% of sea- level Watt
max
, 
followed by 10% increases every minute until volitional 
fatigue. Expired respiratory gases were analysed breath- 
by- breath using a Cosmed K4b2 (Metabolic Company, 
Rome, Italy) portable metabolic system alongside contin-
uous measurements of HR (via three- lead ECG), pulse 
oximetry (oxygen saturation (SpO
2
), Datex Ohmeda 
3900, GE Healthcare, USA), and beat- to- beat measure-
ments of SBP and DBP by photoplethysmography 
(Portapres, Finapres Medical Systems BV, Netherlands). 
The exercise- induced change in SBP and DBP is reported, 
calculated as the difference between pre- exercise and 




To assess EVLW, lung ultrasound was used to detect the 
presence of ultrasound B- lines,18 with these assessments 
performed at 5035 m, immediately prior to and imme-
diately after exercise tests. Ultrasounds were conducted 
using a portable system (MicroMaxx, Sonosite, Bothell, 
Washington, USA) in conjunction with an 8 MHz linear 
transducer. These examinations consisted of an 8- zone 
technique, scanning in the mid- clavicular line in the 
second and third intercostal spaces and the mid- axillary 
line in the fifth and sixth intercostal spaces each side.18 
These points of insonation were marked with permanent 
ink prior to testing to minimise time and ensure the 
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same zones were scanned on each examination. Ultra-
sound examinations were performed by two clinicians 
experienced with this methodology, and pre- exercise and 
postexercise scans for each participant were done by the 
same operator. Ultrasounds were recorded live (Nikon 
D3S, Japan, on video mode) without audio comments. 
Recordings only included participant number and time- 
point of examination (ie, first or second ultrasound). No 
indications for the presence or number of B- Lines were 
made at the time of the ultrasound nor at any time during 
the expedition. Rather, recordings were analysed on 
return to the UK by two blinded experimenters at sepa-
rate sites. The total number of B- lines from each scan was 
taken as the average from these two reviewers. The inter- 
reviewer correlation on B- line count was strong (R=0.92). 
Group allocation was only revealed once recordings had 
been analysed and all B- lines counted.
Data analysis
Independent t- tests were used to test for differences 
between groups at rest and exercise- related time points 
of interest at 5035 m (when measures were not repeated), 
such as, at peak power, immediately postexercise or 
exercise- induced change. Repeated- measures anal-
ysis of variance with pairwise comparisons (Bonferroni 
corrected) was used for between- group comparisons of 
the morning BP assessment during ascent. All data are 
presented as mean±SD and statistical significance was set 
at p<0.05.
Patient and public involvement
This study was supported by the Birmingham Medical 
Research Expeditionary Society, which provided input for 
the conduct of the research. Patients were not included. 
Public involvement was limited to recruitment. Notifica-
tion was given to participants at the time of consent that 
acquisition of personal data was permitted on request. 
Permission was also obtained at this time for the dissemi-
nation of deidentified data within the research team and 
only externally when a reasonable request was submitted 
directly to the corresponding author of the present study 
within 6 months of its publication. A portion of the cohort 
was invited to review the research methods for accuracy 
and readability.
Participants give their written informed consent and 
the study was conducted in agreement with Declaration 
of Helsinki principles. This study did not aim to inves-
tigate safety or efficacy of the already Food and Drug 
Administration (FDA)- approved drug included, thus no 
clinical trial approval was obtained. There were no active 
FDA recalls for the drug for the duration of the study.
RESULTS
Two paired participants did not complete the exercise 
test at high altitude, withdrawn during submaximal inten-
sity steps due to symptomatic abnormalities in the ECG 
recording (unifocal ventricular ectopics and atrial tachy-
cardia) and very low SpO
2
 measures (ie, <55%). For these 
two participants, post- exercise ultrasound scans were still 
conducted following test termination, so EVLW data were 
collected from all 20 participants. For the remaining 
exercise- related measures, data are reported from 18 
paired participants, unless otherwise stated. Such cases 
related to participant’s exercising BP recordings being 
deemed unreliable (eg, Portapres BP signal dropped out, 
n=2) and a missing ultrasound data file (n=1), whereby 
group comparisons were made without the matched pair 
for this measure.
Ascent and resting measures at 5035 m
During ascent, there was no significant difference 
between groups for morning resting measures of SBP 
(group effect: p=0.71), although SBP was on average lower 
in the losartan group at the lower altitudes (figure 1A). 
On average, SBP increased during ascent, although not 
significantly so (p=0.17).
At 5035 m, there was no significant difference between 
groups for resting measures of SpO
2
 (losartan vs placebo: 
79±5 vs 76±6%, p=0.40), HR (80±12 vs 76±15 b/min, 
p=0.50), or SBP (124±16 vs 122±14 mm Hg, p=0.76; 
figure 1).
Exercise at 5035 m: performance and exercise-induced 
responses
Peak power was reduced at high altitude relative to sea- 
level values (p<0.01), with this reduction in power similar 
for both losartan and placebo groups (down 100±29 vs 
91±28 W, respectively, p=0.55; figure 2). At peak power, 
measures of SpO
2
 (70±6 vs 70±5%, p=0.88), VO
2peak
 
(31.3±4.6 vs 34.0±7.2 mL/kg/min, p=0.35), V
E
 (142±38 
vs 146±31 L/min, p=0.81) and HR (146±21 vs 149±24 b/
min, p=0.78) were similar between groups. The increase 
in SBP from rest to peak power was also no different 
between groups (n=14 paired participants: increased by 
80±37 vs 69±33 mm Hg, p=0.56).
Ultrasound B- lines were present in 18/19 participants 
(one pre- exercise scan was lost) prior to the exercise test 
at 5035 m, and present in all 20 participants immediately 
following exercise (figure 3A). Exercise increased B- line 
count in both groups, however, there was no significant 
difference between groups at either the pre- exercise or 
postexercise time points, nor for the change in B- lines 
from resting values (up by: 4.9±4.6 (losartan) vs 7.8±9.8 
(placebo), p=0.44; figure 3B).
DISCUSSION
Exposure to high altitude induces hypertension, both 
systemic and pulmonary, which exacerbates arterial 
hypoxia by means of increasing pulmonary vasoconstric-
tion and V
E
 perfusion mismatching.1 Given that exercise 
also increases BP, especially at higher intensities,19 the 
combination of these two stimuli may exacerbate the like-
lihood of pulmonary hypertension developing into high 
altitude illness (ie, HAPE), but may also be a mechanism 
by which exercise capacity is reduced at high altitude. 
Therefore, we sought to determine the anti- hypertensive 
copyright.













ed: first published as 10.1136/bm
jsem




4 Lucas SJE, et al. BMJ Open Sp Ex Med 2021;7:e000982. doi:10.1136/bmjsem-2020-000982
Open access
effectiveness of losartan to lower altitude- induced 
systemic and pulmonary hypertension and improve 
exercise performance at high altitude (5035 m). Our 
findings, however, showed no beneficial effect of RAAS 
inhibition via this angiotensin II antagonist on resting 
and exercising BP responses, SpO
2
, exercise- induced 
symptomology of pulmonary hypertension, or indeed 
exercise performance at 5035 m. These findings reflect 
the complex nature of this physiological response and 
highlight the need for further research to understand 
the mechanisms and consequences of hypoxic pulmo-
nary vasoconstriction on high- altitude performance.20
The lack of effect on resting BP we observed is consistent 
with findings from Parati and colleagues.12 Specifically, 
while they did show a lowering of ambulatory BP at sea 
level and at 3400 m with the use of the angiotensin- II 
receptor antagonist, telmisartan, its antihypertensive 
efficacy was not evident at 5400 m, similar to our current 
observations at 5035 m. Interestingly, although our 
group differences did not reach statistical significance, 
the losartan group also had lower SBP at altitudes below 
3950 m. Taken together, both studies indicate that these 
anti- hypertensive medications are not effective at higher 
altitudes (eg, >3500 m). These findings have important 
potential clinical implications for hypertensive individ-
uals who wish to travel to high altitudes (eg, >4000 m) 
that are currently receiving antihypertensive treatment, 
the numbers of which are increasing.3 Therefore, a phar-
macological strategy to appropriately treat and manage 
the combined hypertensive effects of hypoxia and exer-
cise is warranted and deserves further study.
Our findings illustrate the utility of using lung ultra-
sound to assess EVLW.13 21 The presence of B- lines 
observed at rest, although low, supports previous obser-
vations that indicate a degree of interstitial oedema is 
frequent at such altitudes in both healthy individuals and 
those with mountain sickness.18 21 The almost universal 
(19/20) increase in EVLW following strenuous exercise 
further implicates exercise as a risk factor for developing 
HAPE and may represent what is increasingly being 
considered as subclinical HAPE.18 Eldridge et al demon-
strated bronchoalveolar lavage samples from healthy 
individuals after heavy exercise in hypoxia that mirrored 
the composition of that seen in early HAPE, which 
persisted for at least 26 hours postexercise.22 Further, 
our group have previously demonstrated that ultra-
sound evidence of exercise- induced pulmonary oedema 
at 4000 m persisted for approximately 4 hours following 
exercise before returning to baseline.13 Taken together, 
these findings indicate an additional pathological process 
is required for the propagation and persistence of fulmi-
nant HAPE on top of a propensity to develop oedema 
following exercise.
Justification for our choice of the angiotensin- II 
receptor antagonist, losartan, over other agents that influ-
ence aspects of the RAAS, was based on previous findings 
that highlighted angiotensin- II’s specific ability to modu-
late acute pulmonary vasoconstriction responses.14 23 
Figure 1 Measures (mean±SD) of resting systolic blood pressure during ascent and arrival to 5035 m (A, n=10 matched pairs), 
and measures of peripheral arterial oxygen saturation (SpO
2
, (B), systolic (C) and diastolic (D) blood pressure measures from 
the first morning routine medical examinations at 5035 m.
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Furthermore, genetic studies have revealed the involve-
ment of several genes associated with the RAAS in 
relation to the physiological response to hypoxia, which 
have included the AGRT1 gene.8 24 Polymorphisms 
within the AGRT1 have specifically been associated with 
the risk for developing HAPE.10 25 26 Thus, we hypothe-
sised that the administration of losartan would elicit 
favourable responses in systemic and pulmonary pres-
sures at high altitude and improve exercise capacity. 
Ultimately, we aimed to determine if losartan could 
be a beneficial agent for the prophylactic treatment of 
HAPE and offset altitude- related impairments in exercise 
capacity. However, based on the findings of the current 
study, a daily dose of losartan at 100 mg appears not to 
be useful in this context. Finally, the development of 
pulmonary oedema at altitude is likely polygenetic and 
multifactorial, thus blockage of a single pathway may not 
be sufficient. It may be that a specific pulmonary vaso-
dilator (eg, nifedipine, a calcium channel blocker) or a 
type-5 phosphodiesterase inhibitor (eg, tadalafil), which 
Figure 2 Comparison of between losartan and placebo groups for the reduction in peak power at 5035 m relative to 
individuals sea- level performance (A, n=9 matched pairs), the exercise- induced increase in systolic blood pressure (B, n=7 
matched pairs), peripheral arterial oxygen saturation (SpO
2
, (C) and heart rate (D) at rest and at peak power (n=9). Data are 
presented as mean±SD. Lower sample size for blood pressure measures were due to unreliable data produced from the 
finometer in at least one matched pair.
Figure 3 Prevalence of extravascular lung water, as indexed by number of ultrasound B- lines, in response to a graded 
exercise test to volitional fatigue at 5035 m. (A) shows absolute count at rest before and then immediately following exercise. 
(B) shows change in number of B- lines induced by the exercise test.
copyright.













ed: first published as 10.1136/bm
jsem




6 Lucas SJE, et al. BMJ Open Sp Ex Med 2021;7:e000982. doi:10.1136/bmjsem-2020-000982
Open access
have been shown to reduce incidence of HAPE among 
susceptible individuals,6 7 is required to prevent exercise- 
induced pulmonary hypertension and improve exercise 
performance at altitude.
Limitations
The relatively small sample size limited this study’s power 
to detect a significant effect of losartan on resting BP and 
prevalence of B- lines induced by exercise. Parati et al’s 
study demonstrated the lower BP effect at 3400 m in a 
sample of 20 taking telmisartan (vs 25 in placebo group). 
Our study sample size was restricted due to difficulties 
and cost of recruiting participants to a remote place for 
an extended time, typical of this type of field research.27 
Second, we did not perform lung ultrasound at sea level 
to assess effect of strenuous sea- level exercise on the 
development of B- lines. However, we have previously 
reported that EVLW is not detected at sea level before 
or after exercise to exhaustion in a similar group of indi-
viduals as studied here.13 The differential diagnosis for 
B- lines includes pneumonitis and interstitial pneumonia. 
However, the pattern of B- lines was typical of pulmonary 
oedema, and our participants were otherwise well with no 
history of chronic lung disease and the observed increase 
is most likely explained by worsening interstitial oedema.
CONCLUSION
Our findings showed that the angiotensin II type- I 
receptor antagonist, losartan, had no observable effect 
on either resting or exercise BP responses at 5035 m, nor 
did it reliably reduce exercise- induced symptomology 
of pulmonary hypertension (as assessed via ultrasound 
quantification of EVLW) or improve arterial saturation. 
These null effects were supported by no observable 
difference in exercise performance. Our findings have 
potential clinical implications for hypertensive individ-
uals who travel to high altitudes (eg, >4000 m) that are 
currently receiving antihypertensive treatment, as they 
may be at greater risk for high altitude illness and cardio-
vascular events since their anti- hypertensive treatments 
appear to exhibit a null effect on BP management.
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